2-47471002-A-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.1699A>T(p.Lys567*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000251.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 25
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:1
The observed stop gained c.1699A>T (p.Lys567Ter) variant in MSH2 gene has been previously reported in multiple individuals affected with MSH2-related disorders (Ewald et al., 2007; Li et al., 2022). The p.Lys567Ter variant is absent in gnomAD Exomes. This variant has been submitted to the ClinVar database as Pathogenic. Computational evidence (MutationTaster - Disease causing) predicts damaging effect on protein structure and function for this variant. The reference amino acid of p.Lys567Ter in MSH2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. This sequence change creates a premature translational stop signal (p.Lys567Ter) in the MSH2 gene. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants in MSH2 gene have been previously reported to be pathogenic (Mangold et al., 2005). For these reasons, this variant has been classified as Pathogenic. -
Lynch syndrome Pathogenic:1
Coding sequence variation introducing premature termination codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Lys567*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 90753). This premature translational stop signal has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 17440950, 21642682). This variant is not present in population databases (ExAC no frequency). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.K567* pathogenic mutation (also known as c.1699A>T), located in coding exon 11 of the MSH2 gene, results from an A to T substitution at nucleotide position 1699. This changes the amino acid from a lysine to a stop codon within coding exon 11. This variant has been identified in multiple probands with Lynch syndrome-associated tumors; several which demonstrated high microsatellite instability and/or loss of MSH2 expression by immunohistochemistry (Ewald J et al. Br J Surg, 2007 Aug;94:1020-7; Bonadona V et al. JAMA, 2011 Jun;305:2304-10; Li Y et al. Cancer Biol Med, 2022 Jun;19:1235-48). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at